Beijing Cancer hospital-Oncology Radiotherapy Department ( Site 0309)

Beijing, Beijing Municipality 100142

0 studies enrolling now · 1 studies all time

What they study most

Carcinoma, Non-Small-Cell Lung

Studies at this site

• Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006) — Running, not enrolling